Checchi Capital Advisers LLC Reduces Stock Position in Humana Inc. $HUM

Checchi Capital Advisers LLC lessened its holdings in Humana Inc. (NYSE:HUM) by 8.8% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,033 shares of the insurance provider’s stock after selling 100 shares during the quarter. Checchi Capital Advisers LLC’s holdings in Humana were worth $252,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of HUM. Revolve Wealth Partners LLC purchased a new position in Humana in the fourth quarter valued at $202,000. UMB Bank n.a. increased its holdings in Humana by 99.5% in the first quarter. UMB Bank n.a. now owns 373 shares of the insurance provider’s stock valued at $99,000 after buying an additional 186 shares during the last quarter. Park Avenue Securities LLC increased its holdings in Humana by 12.8% in the first quarter. Park Avenue Securities LLC now owns 9,743 shares of the insurance provider’s stock valued at $2,578,000 after buying an additional 1,108 shares during the last quarter. Pallas Capital Advisors LLC purchased a new position in Humana in the first quarter valued at $2,136,000. Finally, Yousif Capital Management LLC lifted its position in Humana by 3.4% in the first quarter. Yousif Capital Management LLC now owns 21,764 shares of the insurance provider’s stock valued at $5,759,000 after acquiring an additional 715 shares during the last quarter. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Humana Trading Up 0.0%

NYSE HUM opened at $295.26 on Wednesday. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.95 and a current ratio of 1.95. The firm has a market cap of $35.51 billion, a PE ratio of 22.66, a P/E/G ratio of 1.73 and a beta of 0.42. Humana Inc. has a one year low of $206.87 and a one year high of $315.35. The firm’s fifty day moving average is $277.31 and its two-hundred day moving average is $257.76.

Humana (NYSE:HUM) last posted its quarterly earnings data on Wednesday, July 30th. The insurance provider reported $6.27 EPS for the quarter, missing analysts’ consensus estimates of $6.32 by ($0.05). The business had revenue of $32.39 billion during the quarter, compared to analyst estimates of $31.85 billion. Humana had a net margin of 1.28% and a return on equity of 13.67%. The company’s revenue for the quarter was up 9.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $6.96 earnings per share. Humana has set its FY 2025 guidance at 17.000- EPS. Analysts expect that Humana Inc. will post 16.47 earnings per share for the current year.

Humana Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Friday, September 26th will be paid a $0.885 dividend. The ex-dividend date is Friday, September 26th. This represents a $3.54 dividend on an annualized basis and a yield of 1.2%. Humana’s payout ratio is currently 27.17%.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on HUM. Sanford C. Bernstein boosted their price target on shares of Humana from $269.00 to $341.00 and gave the company an “outperform” rating in a research report on Friday, September 5th. Mizuho set a $300.00 price target on shares of Humana in a research report on Friday. Barclays reduced their price target on shares of Humana from $315.00 to $245.00 and set an “equal weight” rating for the company in a research report on Friday. Morgan Stanley reduced their price target on shares of Humana from $290.00 to $277.00 and set an “equal weight” rating for the company in a research report on Thursday, July 31st. Finally, Guggenheim reissued a “buy” rating on shares of Humana in a research report on Friday, October 3rd. Seven investment analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Humana currently has a consensus rating of “Hold” and an average price target of $293.50.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.